Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients

Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealth’s presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

“Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials.”

Title: “Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients

Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery, M.D., Christopher W. Szeto, Ph.D.

Poster Session and Number: Poster session C (Board #A14)

Location: Moscone West Building

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealth’s GPS Cancer® platform. GPS Cancer® provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics’ proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit www.nantomics.com.

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

NANT

Jen Hodson

Jen@nant.com

562-397-3639

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Genetics Clinical Trials Research Science Biotechnology

MEDIA:

Logo
Logo

NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens with Alternative Mechanism of Action

NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens with Alternative Mechanism of Action

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new real-world data on treatment patterns for patients with advanced colorectal cancer (CRC) during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealth’s presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealth’s Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform. Detailed information from 6,325 treatment plans was analyzed to identify treatment patterns using regorafeniband trifluridine + tipiracilfor advanced CRC patients as third-line of therapy. National Comprehensive Cancer Network (NCCN) guidelines state that regorafenib and trifluridine+tipiracil are both treatment options for patients who have progressed through all available regimens.

Across all 6,325 treatment plans submitted for this patient population, regorafenib (n=217) or trifluridine+tipiracil (n=144) was the submitted treatment in 361 (5.5%) of the treatment plans, making them the 9th and 13th most frequently requested drugs (excluding growth factors, anti-emetics, and leucovorin) in this setting. While the total number of treatment plans for regorafenib was higher than that for trifluridine+tipiracil, the submission of trifluridine+tipiracil has increased over time, consistent with the latter drug’s more recent introduction into the market.

“Our analysis shows that recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action,” said William A. Flood, MD, MS, Chief Medical Officer for Eviti, NantHealth. “As results cannot be fully explained by clinical trial outcome differences, NCCN guidelines preferences, or HEOR measures, we must delve deeper into why these therapeutic patterns exist to further our mission of optimizing patient outcomes and enabling value-based care in oncology. The uncertainty of what constitutes the ‘best’ treatment for this patient population provides an excellent opportunity to employ available data to guide patient-centered decision making and value-based care initiatives.”

Title: “Real world data on treatment patterns of advanced CRC in 3rd line and beyond”

Authors: William A. Flood MD MS, Neil Margolis Ph.D., Vlad Kozlovsky, Sandeep K. Reddy MD

Abstract #56, Poster Session and Number: C – Anal and Colorectal Cancer

Location: Moscone West Building, Level 1, West Hall

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

“Our Eviti platform enables access to near-real time data on physician behavior which can provide unique and critical information to pharma, payers, and provider networks to optimize treatment strategies,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth.

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

MEDIA CONTACT

NANT

Jen Hodson

Jen@nant.com

562-397-3639

KEYWORDS: United States North America California Illinois

INDUSTRY KEYWORDS: Software Practice Management Internet Oncology Health Data Management Hospitals Technology

MEDIA:

Logo
Logo

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS FSCT, MAT, TCNNF, WBAI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Jan. 24, 2020 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:


Mattel, Inc. (MAT)


Class Period: 10/26/2017 – 8/8/2019
Lead Plaintiff Motion Deadline: February 24, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-mat/    


Trulieve Cannabis Corp. (TCNNF)


Class Period: 9/25/2018 – 12/17/2019
Lead Plaintiff Motion Deadline: February 28, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/otc-tcnnf/


Forescout Technologies, Inc. (FSCT)


Class Period: 2/7/2019 – 10/9/2019
Lead Plaintiff Motion Deadline: March 2, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-fsct/    


500.com Limited (WBAI)


Class Period: 4/27/2018 – 12/31/2018
Lead Plaintiff Motion Deadline: March 16, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-wbai/    

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BZUN, FCAU, MYL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Jan. 24, 2020 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:


Fiat Chrysler Automobiles N.V. (FCAU)


Class Period: 2/26/2016 – 11/20/2019
Lead Plaintiff Motion Deadline: January 31, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-fcau/





Baozun Inc. (BZUN)

Class Period: 3/6/2019 – 11/20/2019
Lead Plaintiff Motion Deadline: February 10, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-bzun/


Mylan N.V. (MYL)


Class Period: 5/9/2018 – 5/6/2019
Lead Plaintiff Motion Deadline: February 14, 2020
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-myl/

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

CV SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CV Sciences, Inc. – CVSI

PR Newswire

NEW ORLEANS, Jan. 24, 2020 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CV Sciences, Inc. (OTC: CVSI).  

Kahn Swick & Foti, LLC ("KSF") - - not all law firms are created equal.  Visit www.ksfcounsel.com to learn more about KSF. (PRNewsfoto/Kahn Swick & Foti, LLC)

In 2016, the Company filed a patent application with the U.S. Patent Trademark Office (“USPTO”) for its lead product, CVSI-007. On December 14, 2017, the USPTO issued a final rejection for the Patent Application for CVSI-007, affirming its first rejection previously made on April 27, 2017 and sent to the Company on June 6, 2017. However, the Company failed to disclose the rejection to shareholders, instead consistently touting CVSI-007 as being “patent-pending,” “proprietary,” and “patent-protectable.” Then, on August 20, 2018, the rejections of the patent application and the Company’s failure to disclose them were publicly revealed in a Tweet issued by Citron Research.

Thereafter, the Company and certain of its executives were sued in securities class action lawsuits, charging them with failing to disclose material information during the Class Period, violating federal securities laws. Recently, the court in that consolidated case denied the Company’s motion to dismiss, allowing the case to move forward.

KSF’s investigation is focusing on whether CV’s officers and/or directors breached their fiduciary duties to CV’s shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of CV Sciences, Inc. shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/otc-cvsi/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cv-sciences-investigation-initiated-by-former-louisiana-attorney-general–kahn-swick–foti-llc-investigates-the-officers-and-directors-of-cv-sciences-inc—cvsi-300993114.html

SOURCE Kahn Swick & Foti, LLC

PRUDENTIAL FINANCIAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Prudential Financial, Inc. – PRU

PRUDENTIAL FINANCIAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Prudential Financial, Inc. – PRU

NEW ORLEANS–(BUSINESS WIRE)–
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until January 27, 2020 to file lead plaintiff applications in a securities class action lawsuit against Prudential Financial, Inc. (NYSE: PRU), if they purchased the Company’s securities between February 15, 2019 and August 2, 2019, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

What You May Do

If you purchased securities of Prudential and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-pru/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by January 27, 2020.

About the Lawsuit

Prudential and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the assumptions used by the Company in establishing reserves failed to account for adversely developing mortality experience in its Individual Life business segment; (ii) the Company’s reserves were inadequate to satisfy its future policy benefits liabilities; (iii) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience; and (iv) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.

The case is City of Warren Police And Fire Retirement System v. Prudential Financial, Inc. et al., 19-cv-20839.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

lewis.kahn@ksfcounsel.com

1-877-515-1850

1100 Poydras St., Suite 3200

New Orleans, LA 70163

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

CORRECTING and REPLACINGSOL Global Investments Corp. Disposes of Shares in Frankly Inc. With Proceeds From Sales Being Used for Additional Investment Into Torque ESports Corp. (formerly Millennial ESports Corp.)

CORRECTING and REPLACINGSOL Global Investments Corp. Disposes of Shares in Frankly Inc. With Proceeds From Sales Being Used for Additional Investment Into Torque ESports Corp. (formerly Millennial ESports Corp.)

TORONTO–(BUSINESS WIRE)–
Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

SOL GLOBAL INVESTMENTS CORP. DISPOSES OF SHARES IN FRANKLY INC. WITH PROCEEDS FROM SALES BEING USED FOR ADDITIONAL INVESTMENT INTO TORQUE ESPORTS CORP. (FORMERLY MILLENNIAL ESPORTS CORP.)

SOL Global’s Reinvestment into Torque signifies SOL Global’s commitment to the Frankly, WinView and Torque business combination

SOL Global Investments Corp. (“SOL Global” or the “Company”)(CSE:SOL) (OTCPK: SOLCF) (Frankfurt:9SB) announces that on January 21, 2020, SOL Global disposed of 300,000 common shares (“Common Shares”) of Frankly Inc. (“Frankly”) (TSXV:TLK) through the facilities of the TSX Venture Exchange (the “Disposition”). The consideration received per Common Share under the Disposition was approximately $0.65, for total consideration received of $193,659. The completion of the Disposition, together with other dispositions of Common Shares by SOL Global since the last early warning report of Common Shares disposed of by the Company filed on November 29, 2019 (the “November 29 Report”) resulted in a greater than 2.0% decrease in the 13.81% Common Share holding reported in the November 29 Report.

Immediately before the completion of the Disposition, SOL Global beneficially owned 3,789,100 Common Shares, representing approximately 12.4% of the issued and outstanding Common Shares on a non-diluted basis. Immediately following the completion of the Disposition, SOL Global beneficially owned 3,489,100 Common Shares, representing approximately 11.4% of the issued and outstanding Common Shares on a non-diluted basis.

The completion of the Disposition led to a 1.0% decrease in the Company’s securityholding percentage of the issued and outstanding Common Shares. SOL Global will file an early warning report regarding the Disposition on SEDAR at www.sedar.com within two (2) business days of the filing of this news release.

SOL Global will continue to fund Torque ESports Corp. (“Torque”) during the merger process which may require SOL Global to divest of additional Frankly stock, reducing SOL Global’s ownership to below 10%.

The Company disposed of the securities reported herein for investment purposes. The Company may, depending on market and other conditions, increase or decrease its beneficial ownership in Frankly’s securities, whether in transactions over the open market, by privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities.

As previously announced, on November 22, 2019 Frankly, Winview, Inc. and Torque entered into a three-way business combination. The Company intends to loan all or part of the proceeds from the Disposition into Torque or a subsidiary of Torque. Torque will use the proceeds to facilitate their business prior to the three-way business combination. The reinvestment of these funds into Torque signifies SOL Global’s commitment to the three-way business combination and looks forward to its successful closing and the relaunching of the combined entity, Engine Media Holdings, Inc.

This news release is being issued to comply with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”). An early warning report will be filed on SEDAR in accordance with NI 62-103. To obtain more information or to obtain a copy of the early warning report to be filed in respect of this news release, please contact SOL Global at the contact details noted below.

About SOL Global Investments Corp.

SOL Global is an international investment company with a focus on investing in cannabis and cannabis related companies in legal U.S. states, the hemp and CBD marketplaces and the emerging European cannabis and hemp marketplaces with an objective of providing shareholders with a long term return through capital appreciation, dividends and interest from its investments. If SOL Global believes there is a strategic reason to do so, it may also invest in companies not in the cannabis sector.

The Company’s head office is located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9. Frankly’s head office is located at 50 West 17th Street, 11th Floor, New York, New York, USA, 10011.

Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contain herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative if these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may”, or “will” happen, or by discussions of strategy. Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management of the Company, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond the Company’s control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, but are not limited to: the Company’s ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry; and regulatory or political change. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.

SOL Global Investments Corp.

Peter Liabotis, Chief Financial Officer

Phone: (212) 729-9208

Email: info@solglobal.com

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Finance Agriculture Banking Natural Resources Professional Services

MEDIA:

MEDMEN SHAREHOLDER ALERT: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of MedMen Enterprises Inc. – MMNFF

MEDMEN SHAREHOLDER ALERT: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of MedMen Enterprises Inc. – MMNFF

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of MedMen Enterprises Inc. (OTC: MMNFF). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/otc-mmnff/ to learn more.

The investigation concerns whether MedMen and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

lewis.kahn@ksfcounsel.com

1-877-515-1850

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Opera Limited (OPRA) Who Have Suffered Significant Losses to Contact its Attorneys: Securities Class Action Case Filed

PR Newswire

SAN FRANCISCO, Jan. 24, 2020 /PRNewswire/ — Hagens Berman urges Opera (NASDAQ: OPRA) investors who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses.  A securities class action has been filed against the Company and certain investors may have valuable claims. 

Hagens Berman Sobol Shapiro LLP


Class Period: July 24, 2018 – Jan. 15, 2020


Lead Plaintiff Deadline: Mar. 24, 2020


Sign Upwww.hbsslaw.com/investor-fraud/OPRA 


Contact An Attorney Now:



OPRA@hbsslaw.com

 


844-916-0895

Opera (OPRA) Securities Class Action:

According to the Complaint, Defendants misled investors by misrepresenting and failing to disclose that (1) Opera’s sustainable growth and market opportunity for its browser apps were significantly overstated and (2) Defendants’ funded, owned, or otherwise controlled loan services apps and businesses relied on predatory lending practices, and (3) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera’s financial prospects, especially with respect to its lending apps’ continued availability on the Google Play Store.

The market learned the truth on Jan. 16, 2020, when Hindenburg Research published a scathing report about the Company, accusing Opera of engaging in predatory short-term loans in Africa and India, deploying deceptive “bait and switch” tactics to lure borrowers, and charging egregious interest rates ranging from about 365% – 876%.  According to the report, Opera’s apps are now “in black and white violation of numerous Google rules,” and therefore “this entire line of business is at risk of disappearing or being severely curtailed.”

In addition, the Report accused Opera’s chairman and CEO, Yahui Zhou of diverting $40 million of Company proceeds to entities owned or influenced by Zhou through a slew of questionable related-party transactions that were not adequately disclosed to investors.

In response, the price of Opera ADSs fell sharply on Jan. 16, 2020.  Opera ADSs now trade sharply below Opera’s IPO and secondary offering prices.

“We’re focused on investors’ losses and proving Opera concealed the risks posed by its short term loan business and questionable related-party deals,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased ADSs of Opera and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers:
 Persons with non-public information regarding Opera Limited should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email OPRA@hbsslaw.com.


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-investors-in-opera-limited-opra-who-have-suffered-significant-losses-to-contact-its-attorneys-securities-class-action-case-filed-300993183.html

SOURCE Hagens Berman Sobol Shapiro LLP

Ryerson University decision an assault on democracy, says OFL

TORONTO, Jan. 24, 2020 (GLOBE NEWSWIRE) — The Ontario Federation of Labour (OFL) condemns the ill-conceived and short-sighted decision of Ryerson University to terminate its operating agreement with the Ryerson Students Union (RSU).The RSU has been instrumental in fighting for student autonomy, and student-led change on campus for 72 years.

“This is an attack on student union autonomy and the right for students to independently organize. It undermines the democratic rights of students and student organizations that represent them,” said Ontario Federation of Labour President Patty Coates. “Ryerson is shamefully leaving its student body without the representation they voted for.”

Student unions are an essential democratic institution that bring the voice of the student body to the administration, advocate for student-positive change on campus and in university policy.

“Ryerson is acting against its own students, who stand to lose important services that student unions advocate for and provide, including mental health advocacy, safe space for LGBTQI+ students, campus food bank, and sexual assault support services,” said OFL Secretary-Treasurer Ahmad Gaied.

Conservative cuts to education have affected all levels of education in Ontario. Student unions have also been under attack and have been forced to close services due to the Conservative’s Student Choice Initiative.

“Now is the time when Ryerson should be supporting its student union to succeed, not choosing to turn its back on decades of reliable activism and student democracy,” said OFL Vice-President Janice Folk-Dawson. “Any decisions about the fate of student unions must be done through the proper democratic channels, rather than through a unilateral decision that silences the voices of students.”

The Ontario Federation of Labour is Canada’s largest labour federation, representing 54 unions and one million workers in OntarioFor information, visit www.OFL.ca and follow @OFLabour on Facebook and Twitter.

To arrange interviews or for more information, please contact:

Meagan Perry, Director of Communications
Ontario Federation of Labour
mperry@ofl.ca l 416-894-3456